Business EconomyPosted at: Mar 20 2025 6:42PM


Bharat Biotech forays into Cell & Gene Therapy

Hyderabad, Mar 20 (UNI) Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, on Thursday announced its foray into Cell & Gene Therapy (CGT).
In a release, the Hyderabad based vaccine maker also informed that it's Viral Vector Production at Genome Valley - expanding its expertise from vaccine innovation to leading-edge regenerative and personalised therapies that promise hope for millions.
This ushers in a new era of gene and cell therapies to tackle scientific challenges—such as targeted gene expression, immune system modulation, and long-term cell survival— The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like hemophilia.
The 50,000-square-foot dedicated state-of-the-art CGT facility represents the next milestone in BBIL’s long-standing mission to deliver targeted, life-saving treatments that address unmet clinical needs globally by concentrating on critical conditions such as hematological malignancies and inherited blood disorders.
Outlining the purpose behind establishing India’s only vertically integrated cell and gene therapy facility, Dr. Krishna Ella, Executive Chairman, Bharat Biotech said, “Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today, involving sophisticated processes that require expertise in precise genetic manipulation and specialized manufacturing capabilities.
Bharat Biotech, with its extensive experience and proven excellence in viral vaccine manufacturing is uniquely positioned to master these complexities and produce human-grade vectors at the scale and consistency needed for clinical trials, thus advancing the global fight against rare and complex diseases.”
Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said “Bharat aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily in developed nations or premium institutions. Our established expertise in producing viral vectors are essential for cell and gene therapy applications - the crucial material for anti-cancer and genetic disorders and robust clinical development abilities for QC release".
Additionally, it has capabilities to manufacture multiple platform products for various disease indications, including blood cancers, solid organ cancers, and genetic disorders, Dr. Raches added.
Prof. Krishanu Saha, University of Wisconsin, Madison, said,“My lab has initiated a pioneering collaboration with Bharat Biotech to develop next-generation CAR (chimeric antigen receptor) cell therapies using AI. Ultimately, genuine innovations in both product design and scaling will enhance patient care globally.”

“Cell & Gene Therapy aligns with BBIL’s broader vision of expanding beyond traditional vaccines into personalized medicine. Leveraging our proven expertise in forging strategic global partnerships, this initiative will enable the rapid translation of advanced scientific discoveries—from potent therapeutic vectors to in vivo CAR (chimeric antigen receptor) generation—into real-world solutions.” Dr. Krishna Ella added.
UNI KNR CS
Please log in to get detailed story.
Tags: #Bharat Biotech forays into Cell & Gene Therapy
More News

Chola MS records Rs 8,328 Cr GWP

27 Apr 2025 | 5:48 PM

Chennai, Apr 27 (UNI) Cholamandalam MS General Insurance Company Ltd (Chola MS), a joint venture between the Murugappa Group and the Mitsui Sumitomo Insurance Group (Japan), has ended FY 2025 with a gross written premium (GWP) of Rs 8,328 crores, a growth of 9.61 % (higher than industry growth).

see more..

Rachana Construction Ltd unveils Rs 300 Cr road project to revamp Kolhapur's connectivity

26 Apr 2025 | 10:07 PM

Pune, Apr 26 (UNI) Infrastructure & Construction company Rachana Construction Limited has undertaken a transformative Rs 300 crore road infrastructure project in Kolhapur aimed at enhancing regional connectivity, easing traffic congestion and fostering economic growth.

see more..
Invest Kerala Summit: Projects worth Rs 4,410 crore to start in May, says P Rajeeve

Invest Kerala Summit: Projects worth Rs 4,410 crore to start in May, says P Rajeeve

26 Apr 2025 | 6:52 PM

Thiruvananthapuram, Apr 26 (UNI) Kerala Minister for Industries, P Rajeeve on Saturday said works on 13 projects with a total investment of Rs 4,410 crore yielded by the Invest Kerala Global Summit (IKGS 2025) will commence in May.

see more..
Kottayam-Kochi rubber market rates

Kottayam-Kochi rubber market rates

26 Apr 2025 | 5:52 PM

Kottayam, Apr 26 (UNI) Following were the market rates of rubber per quintal announced by the Rubber Board here on Saturday.

see more..

SICCI holds Executive Round Table on doing business with Indonesia

26 Apr 2025 | 5:22 PM

Chennai, Apr 26 (UNI) The Southern India Chamber of Commerce and Industry (SICCI)
organized an Executive Round Table on Doing Business with Indonesia at the Indonesia
Trade Promotion Center in Chennai on Saturday.

see more..